TrialBMC health services research2023

Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system.

Chen Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.